Self-perceived stress among young women was significantly associated with increased risk for early-onset cryptogenic ischemic ...

The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent.

There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...

Self-perceived stress is associated with cryptogenic ischemic stroke (CIS), according to a study published online.

The discovery of a novel approach to promote cardiomyocyte proliferation offers new hope for the treatment of ischemic heart failure.

Researchers demonstrated a significant association between smoking status and cryptogenic ischemic stroke in young men.

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...

Europe, with a global market share of 32.7% in 2022, followed North America in the adoption of ischemic stroke aspiration systems. Germany, with a strong manufacturing industry base, contributed to ...

A study has found that patients with ischemic stroke and COVID-19, compared with patients without COVID-19, experience worse recovery outcomes.

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.